Methylation of the RASSF1A and RARβ genes as a candidate biomarker for lung cancer

Li,Wen; Deng,Jing; Jiang,Pei; Zeng,Xiaoxi; Hu,Shunqin; Tang,Jianxin

doi:10.3892/etm.2012.517

Methylation of the RASSF1A and RARβ genes as a candidate biomarker for lung cancer

Authors:
- Wen Li
- Jing Deng
- Pei Jiang
- Xiaoxi Zeng
- Shunqin Hu
- Jianxin Tang
View Affiliations

Affiliations: Hunan Key Laboratory of Green Packaging and Biological Nanotechnology, Hunan University of Technology, Zhuzhou, Hunan 412007, P.R. China
Published online on: March 15, 2012 https://doi.org/10.3892/etm.2012.517
Pages: 1067-1071

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Promoter methylation of the RASSF1A and RARβ genes has been associated with susceptibility to different types of cancer. In addition, RASSF1A and RARβ methylation plays an important role in the pathogenesis of lung cancer. We investigated the aberrant promoter methylation of RASSF1A and RARβ in lung cancer patients using methylation-speciﬁc polymerase chain reaction (MSP). Aberrant promoter methylation of the RASSF1A gene was detected in 45 of 56 (80.36%) cancer patients and aberrant promoter methylation of the RARβ gene was found in 48 of 56 (85.71%) cases; promoter methylation of both genes was found in 42 of 56 (75%) lung cancer cases. None of the 52 samples from controls exhibited DNA methylation in these two target genes. Methylation was significantly associated with the lung cancer cases compared to controls for the RASSF1A gene (adjusted OR=7.50; 95% CI, 3.935-14.296; p<0.001); similar results were obtained for methylation of the RARβ gene (adjusted OR=5.727; 95% CI, 3.348-9.797; p<0.001). In addition, the association remained significant in these two target genes (adjusted OR=8.429; 95% CI, 4.205-16.896; p<0.001). Our results indicated that the high percentage of promoter methylation in the RARβ and RASSF1A genes indicate their important role in the development of lung cancer in the population studied, and that risk of lung cancer for carriers positive for both genes is higher than in single-gene positive carriers, which may serve as a useful marker for prognosis and a target for the treatment of lung cancer.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer Statistics. CA Cancer J Clin. 56:106–130. 2006.
2.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
3.	Jin YT, Xu YC, Yang RD, Huang CF, Xu CW and He XZ: Familial aggregation of lung cancer in a high incidence area in China. Br J Cancer. 92:1321–1325. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
5.	Jemal A, Tiwael RC, Murray T, et al: Cancer statistics. CA Cancer J Clin. 54:92–119. 2004.
6.	Hirsch FR, Merrick DT and Franklin WA: Role of biomarkers for early detection of lung cancer and chemoprevention. Eur Respir J. 19:1151–1158. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Anglim PP, Alonzo TA and Laird-Offringa IA: DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer. 23:812008. View Article : Google Scholar : PubMed/NCBI
8.	Nephew KP: What will it take to obtain DNA methylation markers for early cervical cancer detection. Gynecol Oncol. 112:291–292. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, Wang J and Chen L: Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 303:21–28. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Choi JE, Kim DS, Kim EJ, Chae MH, Cha SI, Kim CH, Jheon S, Jung TH and Park JY: Aberrant methylation of ADAMTS1 in non-small cell lung cancer. Cancer Genet Cytogenet. 187:80–84. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K and Gao B: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P and Maher ER: Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene. 22:147–150. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Grote HJ, Schmiemann V, Geddert H, Bocking A, Kappes R and Gabbert HE: Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer. 108:129–134. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Wang Y, Yu Z, Wang T, Zhang J, Hong L and Chen L: Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer. 56:289–294. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Maruyama R, Toyooka S, Toyooka KO, et al: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 8:514–519. 2002.PubMed/NCBI
16.	Neyaz MK, Kumar RS, Hussain S, et al: Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population. Biomarkers. 13:597–606. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2(Suppl 1): 4–11. 2005. View Article : Google Scholar
18.	Hesson LB, Cooper WN and Latif F: The role of RASSF1A methylation in cancer. Dis Markers. 23:73–87. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C and Lahm H: Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer. 54:109–116. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, Fukuyama Y, Iizasa T, Aoe M, Date H, Fujisawa T, Shimizu N and Gazdar AF: The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer. 91:771–774. 2004.PubMed/NCBI
21.	Toyooka S, Suzuki M, Tsuda T, Toyooka KO, Maruyama R, Tsukuda K, Fukuyama Y, Iizasa T, Fujisawa T, Shimizu N, Minna JD and Gazdar AF: Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer. 110:462–464. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, et al: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer. 103:153–160. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK and Risk JM: Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer. 94:561–568. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Chan EC, Lam SY, Tsang KW, Lam B, Ho JC, Fu KH, Lam WK and Kwong YL: Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalveolar lavage. Clin Cancer Res. 8:3741–3746. 2002.PubMed/NCBI
25.	Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H and Tanimoto M: Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 11:1219–1225. 2005.PubMed/NCBI
26.	Virmani AK, Rathi A, Zöchbauer-Müller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD and Gazdar AF: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst. 92:1303–1307. 2000. View Article : Google Scholar : PubMed/NCBI
27.	Zöchbauer-Müller S, Minna JD and Gazdar AF: Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist. 7:451–457. 2002.PubMed/NCBI